STK-001 ( DrugBank: - )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
140ドラベ症候群2

140. ドラベ症候群


臨床試験数 : 104 薬物数 : 61 - (DrugBank : 14) / 標的遺伝子数 : 48 - 標的パスウェイ数 : 63
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04740476
(ClinicalTrials.gov)
January 21, 20212/2/2021An Open-Label Extension Study of STK-001 for Patients With Dravet SyndromeAn Open-Label Extension Study for Patients With Dravet Syndrome Who Previously Participated in Studies of STK-001Dravet SyndromeDrug: STK-001Stoke Therapeutics, IncNULLEnrolling by invitation30 MonthsN/AAll48Phase 2United States
2NCT04442295
(ClinicalTrials.gov)
June 3, 20208/6/2020An Open-Label Study to Investigate the Safety of Single and Multiple Ascending Doses in Children and Adolescents With Dravet SyndromeAn Open-Label Study to Investigate the Safety and Pharmacokinetics of Single and Multiple Ascending Doses of Antisense Oligonucleotide STK-001 in Children and Adolescents With Dravet SyndromeDravet SyndromeDrug: STK-001 - Single Ascending Doses;Drug: STK-001 - Multiple Ascending DosesStoke Therapeutics, IncNULLRecruiting2 Years18 YearsAll70Phase 1/Phase 2United States